A prospective, non-interventional study of the effectiveness, safety, and health related outcomes in patients with moderate to severe active rheumatoid arthritis receiving filgotinib (FILOSOPHY)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/48323
• EU PAS number:
  EUPAS39767
• Study ID:
  48323
• Official title and acronym:
  A prospective, non-interventional study of the effectiveness, safety, and health related outcomes in patients with moderate to severe active rheumatoid arthritis receiving filgotinib (FILOSOPHY)
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  Germany

  Italy

  Netherlands

  Spain

  United Kingdom
• Study description:
  To describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis receiving filgotinib in real-world setting.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Alfasigma

Italy

Study timelines

Date when funding contract was signed

Actual: 06/04/2021

Study start date

Actual: 11/05/2021

Date of final study report

Planned: 30/06/2029

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Alfasigma S.p.A

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

ClinicalTrials.gov Identifier: https://clinicaltrials.gov/ct2/show/NCT04871919